Novo Nordisk A/S ADR buy BTIG Research
Start price
29.03.23
/
50%
€144.50
Target price
29.03.24
€28.58
Performance (%)
-16.96%
End price
30.03.24
€120.00
Summary
This prediction ended on 30.03.24 with a price of €120.00. The price of Novo Nordisk A/S ADR has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -16.96%. Dividends of €1.43 are taken into consideration when calculating the performance. BTIG_Research has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Novo Nordisk A/S ADR | 3.278% | 3.278% | -24.933% | -68.822% |
| iShares Core DAX® | 1,72 % | 3,37 % | 5,89 % | 52,38 % |
| iShares Nasdaq 100 | -4,56 % | -4,24 % | 21,39 % | 72,45 % |
| iShares Nikkei 225® | -7,12 % | -11,87 % | 42,36 % | 57,58 % |
| iShares S&P 500 | -0,89 % | 1,69 % | 19,49 % | 62,15 % |
Comments by BTIG_Research for this prediction
In the thread Novo Nordisk A/S ADR diskutieren
Novo Nordisk A/S (NYSE: NVO) had its price target raised by analysts at BTIG Research from $20.00 to $31.00. They now have a "buy" rating on the stock.
Ratings data for NVO provided by MarketBeat
In the thread Trading Novo Nordisk A/S ADR
Die von BTIG_Research gewählte maximale Laufzeit wurde überschritten